CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The goal of this clinical research study is to learn if Niraparib can help to control metastatic pancreatic cancer. The safety of t...
Phase 2
Kansas City, Kansas, United States and 5 other locations
open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic...
Phase 1, Phase 2
Kansas City, Kansas, United States and 15 other locations
Researchers want to discover if the new drug "TG01" will work with participants' bodies to help their immune system attack any cancer cells ...
Phase 2
Kansas City, Missouri, United States and 4 other locations
stomach cancer, gastroesophageal junction cancer, (GEJ cancer) or pancreatic cancer. GEJ is where the t...
Phase 1
Westwood, Kansas, United States and 37 other locations
The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in people with metastatic pancreatic...
Phase 1, Phase 2
Westwood, Kansas, United States and 4 other locations
This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors...
Phase 2
Fairway, Kansas, United States and 71 other locations
and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers...
Phase 2
Kansas City, Kansas, United States and 65 other locations
This is a phase 1 first in human, dose escalation trial of GP-2250 administered in combination with gemcitabine in subjects with advanced pancreatic...
Phase 1
Fairway, Kansas, United States and 4 other locations
of care. It is being tested against advanced and/or metastatic solid tumors including gastric, gastroesophageal junction, pancreatic...
Phase 1, Phase 2
Kansas City, Kansas, United States and 17 other locations
as PK and pharmacodynamics of XL309 (previously ISM3091) administered alone or in combination with olaparib in subjects with advanced solid tumors...
Phase 1
Kansas City, Missouri, United States and 11 other locations
Clinical trials
Research sites
Resources
Legal